| Literature DB >> 34980892 |
Jeeranan Manokawinchoke1,2, Phoonsuk Limraksasin1,2, Hiroko Okawa1, Prasit Pavasant2, Hiroshi Egusa3,4, Thanaphum Osathanon5.
Abstract
In vitro manipulation of induced pluripotent stem cells (iPSCs) by environmental factors is of great interest for three-dimensional (3D) tissue/organ induction. The effects of mechanical force depend on many factors, including force and cell type. However, information on such effects in iPSCs is lacking. The aim of this study was to identify a molecular mechanism in iPSCs responding to intermittent compressive force (ICF) by analyzing the global gene expression profile. Embryoid bodies of mouse iPSCs, attached on a tissue culture plate in 3D form, were subjected to ICF in serum-free culture medium for 24 h. Gene ontology analyses for RNA sequencing data demonstrated that genes differentially regulated by ICF were mainly associated with metabolic processes, membrane and protein binding. Topology-based analysis demonstrated that ICF induced genes in cell cycle categories and downregulated genes associated with metabolic processes. The Kyoto Encyclopedia of Genes and Genomes database revealed differentially regulated genes related to the p53 signaling pathway and cell cycle. qPCR analysis demonstrated significant upregulation of Ccnd1, Cdk6 and Ccng1. Flow cytometry showed that ICF induced cell cycle and proliferation, while reducing the number of apoptotic cells. ICF also upregulated transforming growth factor β1 (Tgfb1) at both mRNA and protein levels, and pretreatment with a TGF-β inhibitor (SB431542) prior to ICF abolished ICF-induced Ccnd1 and Cdk6 expression. Taken together, these findings show that TGF-β signaling in iPSCs enhances proliferation and decreases apoptosis in response to ICF, that could give rise to an efficient protocol to manipulate iPSCs for organoid fabrication.Entities:
Mesh:
Substances:
Year: 2022 PMID: 34980892 PMCID: PMC8724316 DOI: 10.1038/s41368-021-00151-3
Source DB: PubMed Journal: Int J Oral Sci ISSN: 1674-2818 Impact factor: 6.344
Fig. 1Differential gene expression profiles of intermittent compressive force (ICF)-treated iPSCs. The experimental scheme is shown in (a). Mouse induced pluripotent stem cells (iPSCs) were treated with ICF in serum-free conditions for 24 h. Cell viability was investigated using the MTT assay (b–d). RNA sequencing analysis was performed. Heat map shows the top 50 significant differentially regulated genes (e)
Top 20 significantly upregulated and downregulated genes in the ICF-treated mouse iPSCs
| Items | Gene symbol | Gene name | Log2FC | FDR |
|---|---|---|---|---|
| Upregulated genes | Metallothionein 2 | 1.679 881 12 | 1.92E-57 | |
| Zinc finger protein 365 | 1.414 175 91 | 1.92E-41 | ||
| Metallothionein 1 | 1.379 982 17 | 4.92E-35 | ||
| Inka box actin regulator 2 | 1.780 233 32 | 3.48E-32 | ||
| Solute carrier family 30 (zinc transporter), member 1 | 1.095 122 89 | 2.64E-19 | ||
| RIKEN cDNA 1700007K13 gene | 1.055 539 59 | 1.68E-18 | ||
| Pleckstrin homology-like domain, family A, member 3 | 0.920 961 22 | 1.09E-17 | ||
| Mitogen-activated protein kinase-activated protein kinase 3 | 0.761 985 97 | 1.11E-17 | ||
| B cell translocation gene 2, anti-proliferative | 0.700 049 | 1.50E-16 | ||
| CUGBP, Elav-like family member 5 | 0.844 8561 7 | 1.32E-14 | ||
| Carnitine palmitoyltransferase 1c | 0.636 578 96 | 3.96E-14 | ||
| Neurofilament, heavy polypeptide | 0.858 813 64 | 4.43E-14 | ||
| Polo-like kinase 2 | 1.017 012 41 | 6.14E-14 | ||
| Growth arrest specific 6 | 0.602 381 47 | 1.24E-13 | ||
| Melanoma cell adhesion molecule | 0.904 323 58 | 3.62E-12 | ||
| Endoglin | 0.604 656 63 | 4.82E-12 | ||
| Cyclin G1 | 0.878 373 39 | 1.06E-11 | ||
| Zinc finger protein 365 | 0.575 425 24 | 1.25E-11 | ||
| Sestrin 2 | 0.521 310 1 | 2.36E-11 | ||
| Synaptotagmin-like 1 | 1.102 422 23 | 4.50E-11 | ||
| Downregulated genes | BCL2/adenovirus E1B interacting protein 3 | −2.220 347 | 1.19E-74 | |
| Phosphoglycerate kinase 1 | −1.173 744 | 2.75E-64 | ||
| Solute carrier family 16 (momocarboxylic acid transporters), member 3 | −2.000 059 7 | 9.23E-59 | ||
| Alpha-2-macroglobulin | −2.577 263 7 | 4.06E-46 | ||
| Ankyrin repeat domain 37 | −2.275 651 2 | 4.72E-46 | ||
| Lactate dehydrogenase A | −1.538 845 6 | 6.06E-44 | ||
| Phosphoglycerate kinase 1 | −1.366 441 4 | 7.39E-37 | ||
| Aldolase C, Fructose-bisphosphate | −1.896 344 9 | 1.16E-35 | ||
| Adrenomedullin | −2.304 846 3 | 3.42E-35 | ||
| Amine oxidase, copper containing 3 | −2.208 889 8 | 2.51E-34 | ||
| Uridine phosphorylase 1 | −1.347 068 4 | 2.92E-34 | ||
| Triosephosphate isomerase 1 | −1.246 284 9 | 7.86E-33 | ||
| Very low density lipoprotein receptor | −1.122 410 4 | 4.69E-28 | ||
| Aldolase A, Fructose-bisphosphate | −1.171 554 2 | 8.41E-28 | ||
| Cyclin G2 | −1.030 579 6 | 2.81E-27 | ||
| Lymphoid enhancer binding factor 1 | −1.395 389 8 | 1.48E-26 | ||
| Riken cDNA 1700029P11 gene | −1.043 410 5 | 8.56E-26 | ||
| Glutamate receptor, ionotropic, NMDA1 (zeta1) | −1.880 521 9 | 1.84E-25 | ||
| Malic enzyme 1, NADP(+)-dependent, cytosolic | −0.767 628 1 | 2.15E-25 | ||
| Solute carrier family 2 (facilitated glucose transporter), member 1 | −1.269 661 4 | 1.88E-24 |
Fig. 2Gene ontology analyses of the upregulated and downregulated genes. The differentially regulated genes were mainly associated with metabolic process, membrane, and protein binding in the categories of biological process (a, b), cellular component (c, d), and molecular function (e, f), respectively
Top 10 KEGG enriched pathways for upregulated and downregulated genes in ICF-treated mouse iPSCs
| Items | ID | Name | Number of Genes | FDR |
|---|---|---|---|---|
| Upregulated pathway | mmu04115 | p53 signaling pathway-Mus musculus (mouse) | 22 | 2.95e-12 |
| mmu05206 | MicroRNAs in cancer-Mus musculus (mouse) | 19 | 6.04e-04 | |
| mmu03460 | Fanconi anemia pathway-Mus musculus (mouse) | 8 | 9.7e-02 | |
| mmu05218 | Melanoma-Mus musculus (mouse) | 9 | 1.69e-01 | |
| mmu01524 | Platinum drug resistance-Mus musculus (mouse) | 9 | 2.3e-01 | |
| mmu04110 | Cell cycle-Mus musculus (mouse) | 12 | 2.3e-01 | |
| mmu03440 | Homologous recombination-Mus musculus (mouse) | 6 | 2.54e-10 | |
| mmu04068 | FoxO signaling pathway-Mus musculus (mouse) | 12 | 3.18e-01 | |
| mmu05215 | Prostate cancer-Mus musculus (mouse) | 9 | 3.34e-01 | |
| mmu00514 | Other types of O-glycan biosynthesis-Mus musculus (mouse) | 4 | 3.34e-01 | |
| Downregulated pathway | mmu01230 | Biosynthesis of amino acids -Mus musculus (mouse) | 25 | 5.48e-11 |
| mmu01200 | Carbon metabolism-Mus musculus (mouse) | 30 | 6.42e-11 | |
| mmu01100 | Metabolic pathways-Mus musculus (mouse) | 130 | 6.42e-11 | |
| mmu00010 | Glycolysis/gluconeogenesis-Mus musculus (mouse) | 19 | 9.15e-08 | |
| mmu00100 | Steroid biosynthesis-Mus musculus (mouse) | 10 | 8.04e-07 | |
| mmu00030 | Pentose phosphate pathway-Mus musculus (mouse) | 11 | 2.74e-05 | |
| mmu00500 | Starch and sucrose metabolism-Mus musculus (mouse) | 11 | 3.36e-05 | |
| mmu04066 | HIF-1 signaling pathway-Mus musculus (mouse) | 20 | 5.81e-05 | |
| mmu03010 | Ribosome-Mus musculus (mouse) | 22 | 2.56e-04 | |
| mmu00520 | Amino sugar and nucleotide sugar metabolism -Mus musculus (mouse) | 12 | 2.81e-04 |
Fig. 3ICF regulates the P53 and cell cycle pathways in iPSCs. RNA sequencing analysis of iPSCs treated with ICF and control was performed using the Kyoto Encyclopedia. Heat map illustrates differentially expressed genes in the P53 signaling pathway and cell cycle pathways (a, b). Graph represents the mRNA expression of selected genes (Ccnd1, Ccng1, and Cdk6) from RNA sequencing results (c–e). Bars indicate significant difference between conditions (**P < 0.01)
Fig. 4ICF promotes cell cycle progression. The experimental scheme is illustrated in (a). Cell cycle analysis of conditions: (1) iPSCs were treated with ICF for 24 h in serum-free medium (b, c), and (2) 24 h after loading, the cells were maintained in normal growth medium for 48 h (e, f). The proliferative index in conditions 1 and 2 is shown in (d, g). Bars indicate a significant difference between conditions (*P < 0.05. **P < 0.01)
Fig. 5ICF reduces the number of early apoptotic cells. iPSCs were treated with ICF for 24 h in serum-free medium. Cells were stained with Annexin V and propidium iodide (PI). The percentage of early and late apoptotic cells is shown in (a, b). Bars indicate a significant difference between conditions (**P < 0.01)
Fig. 6ICF regulated cell cycle-related gene expression via the TGF-β signaling pathway. iPSCs were treated with ICF in serum-free medium. Tgfb1 mRNA expression was investigated using real-time PCR at 2, 8, and 24 h (a) and Tgfb1 protein expression was determined by ELISA (b) and immunofluorescence staining (c) at 24 h. DAPI was used for nuclear staining. Scale bars: 50 μm. In the TGF-β inhibition experiment, cells were treated with SB431542 (4 μmol·L−1) for 30 min prior to exposure to the force. The experimental scheme is illustrated in (d). The mRNA of Ccnd1, Ccng1, and Cdk6 is shown in (e–g). The protein expression of Ccnd1 was examined using western blot analysis (h). Bars indicate a significant difference between conditions (*P < 0.05, **P < 0.01)